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ABSTRACT
The overall survival for adults with malignant glioma (glioblastoma) remains
poor despite advances in radiation and chemotherapy. One of the mechanisms by
which cancer cells develop relative resistance to treatment is through de-regulation
of endoplasmic reticulum (ER) homeostasis. We have recently shown that ABCG1,
an ATP-binding cassette transporter, maintains ER homeostasis and suppresses ER
stress-induced apoptosis in low-grade glioma. Herein, we demonstrate that ABCG1
expression is increased in human adult glioblastoma, where it correlates with poor
survival in individuals with the mesenchymal subtype. Leveraging a mouse model
of mesenchymal glioblastoma (NPcis), shRNA-mediated Abcg1 knockdown (KD)
increased CHOP ER stress protein expression and resulted in greater NPcis glioma
cell death in vitro. Moreover, Abcg1 KD reduced NPcis glioma growth and increased
mouse survival in vivo. Collectively, these results demonstrate that ABCG1 is critical
for malignant glioma cell survival, and might serve as a future therapeutic target for
these deadly brain cancers.

identified by their expression of the prominin-1 cell
surface marker, CD133 [6, 7], GSCs can be enriched by
antibody-mediated isolation, and shown to possess unique
properties such as radioresistance and chemoresistance
not shared with normal brain neural stem cells (NSCs)
[8–10]. Another of these markers is the ABCG2 protein,
which identifies the “side population”, a subset of stem
cells hypothesized to be enriched for cancer propagation
abilities [9, 11].
Similar to ABCG2, ABCG1 belongs to a large
family of ATP-binding cassette proteins involved in
cellular transport [12, 13], where it mainly directs lipid
transport [14, 15]. In this regard, we recently leveraged
a low-grade glioma mouse model of Neurofibromatosis
type 1 (NF1)-associated optic glioma to identify and
characterize low-grade glioma (LGG) cancer stem cells
(LG-GSCs) [16]. Similar to their malignant glioma
counterparts, these LG-GSCs were capable of long-term
self-renewal, multi-lineage differentiation, and forming
low-grade glioma-like lesions following explantation
into immunocompetent mice. However, ABCG2 was not
highly expressed in these murine LG-GSCs, consistent
with an absence of a side population following Hoechst
33342 flow cytometry. Instead, ABCG1 was highly

INTRODUCTION
Brain tumors represent the fourth leading cause
of cancer-related death in adults, where high-grade glial
neoplasms (malignant gliomas) predominate [1]. These
malignant gliomas are classified by the World Health
Organization (WHO) as grade III (anaplastic astrocytoma,
anaplastic oligodendroglioma, and anaplastic mixed
oligoastrocytoma) or IV (glioblastoma) astrocytomas,
commonly occurring in individuals between the ages of
45 and 75 years [2]. Unfortunately, survival following
the diagnosis of a glioblastoma is dismal, with most
patients dying within 12–16 months despite aggressive
surgical, radiation, and chemotherapy management
[1, 3]. Since these cancers are thought to be maintained
by cells with stem cell-like properties (glioma stem cells;
GSCs), intense focus over the past decade has centered
on understanding the critical pathways that govern GSC
growth and differentiation [4, 5].
In this regard, a large number of studies have
revealed that GSCs are capable of long-term self-renewal,
multi-lineage differentiation, and the generation of
histologically-similar tumors following implantation
into immunocompromised rodent brains [6]. Most often
www.impactjournals.com/oncotarget
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gene mutation [17]. Moreover, using multivariate Cox
hazard regression analysis with adjustment for both age
and Karnofsky Performance Score (KPS), the negative
prognostic value of ABCG1 expression in mesenchymal
GBM patient survival remained significant (P = 0.017;
Figure 1D). Together, these findings demonstrate increased
ABCG1 expression in human malignant gliomas, where it
is associated with reduced survival in patients harboring
the mesenchymal glioblastoma subtype.

enriched in both murine and human LG-GSCs relative to
their non-neoplastic NSC counterparts, where it served
to protect these cells from ER stress-mediated cell death
(apoptosis).
Based on the controversial use of ABCG2 as a
marker of CSCs [11] and the recent identification of
ABCG1 as a critical mediator of LG-GSC survival, we
sought to determine whether ABCG1 was important
for high-grade (glioblastoma) survival. In this report,
we demonstrate that ABCG1 expression negatively
correlates with survival in patients with glioblastoma of
the mesenchymal subtype. Leveraging a mouse model
of mesenchymal glioblastoma (NPcis), characterized by
Nf1 and Trp53 loss, we show that shRNA-mediated Abcg1
knockdown increases ER stress-induced apoptosis in vitro
as well as improves the survival of immunocompetent
mice with glioblastoma in vivo. Collectively, these results
establish ABCG1 as another potential biomarker for
high-grade glioma survival relevant to future brain tumor
therapeutic targeting.

Abcg1 knockdown decreases glioblastoma cell
growth in vitro
In the glioblastoma mesenchymal molecular
subtype, NF1 loss is frequently associated with TP53
mutation [17]. Consistent with this observation, mice
harboring germline inactivating mutations in both the
Nf1 and Trp53 genes residing on the same chromosome
(NPcis mice) spontaneously develop high-grade gliomas
[18, 19]. Moreover, derivative glioma cells from these
NPcis mouse tumors exhibit bi-allelic loss of the Nf1 and
Trp53 genes in addition to increased PDGFRα expression,
molecular features also observed in human mesenchymal
glioblastomas [17, 20, 21]. Given the correlation between
ABCG1 expression and overall survival in patients
with mesenchymal subtype glioblastoma, we sought
to determine whether ABCG1 might be important for
NPcis glioma growth using lentivirus-mediated shRNA
knockdown in two independently-generated NPcis highgrade glioma cell lines (K1861 and K4622; [22]). First,
we confirmed Abcg1 knockdown using two distinct
shRNA constructs by Western blotting (Figure 2A; ~50%
protein reduction). Following Abcg1 knockdown, K1861
cells exhibited morphological changes (e.g., rounding)
suggestive of cell death (Figure 2B). Consistent with
these cellular changes, reduced cell growth (% Ki67+
cells; Figure 2C) and increased apoptosis was observed
(% cleaved caspase-3+ cells; Figure 2C) relative to shRNA
controls. Identical results were also observed using the
K4622 high-grade glioma cell line (Figure S2).

RESULTS
Glioblastoma ABCG1 expression is associated
with reduced patient survival
We have recently shown that human low-grade
(pilocytic astrocytoma) glioma specimens exhibit
increased ABCG1 expression [16]. To determine
whether ABCG1 expression was similarly increased in
human glioblastoma specimens, two sets of experiments
were performed. Using the one available GEO dataset
containing normal reference tissue (astrocytes;
GSE15824), we found that ABCG1 expression was
increased in glioblastoma tumors (697 ± 554, 230913_at
probe set; 428 ± 305, 232081_at probe set) relative to
astrocytes (11.5 ± 1.1, 230913_at probe set; 13.9 ± 8.1,
232081_at probe set). Similarly, increased ABCG1
immunoreactivity was observed in representative tumor
specimens from human patients with glioblastoma (n = 16)
relative to normal brain controls (n = 7) (Figure 1A and S1).
Next, we sought to determine whether ABCG1
expression was associated with clinical outcome (overall
survival) in patients with high-grade glioma (GSE16011),
the majority of whom did not receive prior chemotherapy.
Using a total of 159 glioblastoma patients dichotomized by
the median of ABCG1 expression, there were no significant
survival differences between patients harboring gliomas
with low versus high ABCG1 gene expression (Figure 1B).
However, when the analysis was stratified by glioblastoma
molecular subtype, high ABCG1 expression correlated
with shorter overall survival only in the mesenchymal
subgroup (Figure 1C), a subtype characterized by NF1
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Abcg1 knockdown increases ER stress and
glioblastoma cell apoptosis
Since Abcg1 confers a survival advantage to LGGSCs by suppressing ER stress [16], we examined the
expression of BiP and CHOP, two markers of ER stress.
Following Abcg1 knockdown (45–54% protein reduction)
in K1861 and K4622 glioblastoma cells, there was
increased CHOP expression (2.3 and 3-fold, respectively)
and caspase-3 cleavage (1.5 and 2.2-fold, respectively)
relative to controls (Figure 3). However, in contrast to
LG-GSCs, there was no change in BiP expression upon
Abcg1 reduction.

2

Oncotarget

groups relative to control shRNA K1861-implanted mice
(#1, p = 0.042; #2, p = 0.0098; Figure 4B). Over the
120 days of observation, mice in the shRNA control group
became ill and had to be euthanized (median survival
= 37 days). However, in striking contrast, mice receiving
Abcg1-shRNA K1861 glioblastoma cells had median
survivals of 64 (P < 0.0001) and 98 (P < 0.0001) days,
respectively (Figure 4C). While shAbcg1-#2 was slightly
more effective at reducing Abcg1 protein expression
than shAbcg1-#1 (15% versus 30% of shLacZ levels),
which might account for the observed lower BLI signal
observed in mice receiving 1861 cells with shAbcg1-#2
versus shAbcg1-#1 (P = 0.0226), there was no difference
in survival (P = 0.1426).
To determine whether Abcg1 knockdown resulted
in increased glioblastoma apoptosis in vivo, Ki67 and
TUNEL immunostaining were performed on the tumors
following euthanasia. Consistent with the above in vitro
findings, shAbcg1 K1861 tumors had reduced Abcg1
protein expression and fewer Ki67+ cells relative to

Abcg1 knockdown reduces glioma growth and
mouse survival in vivo
To determine whether Abcg1 knockdown also
decreases glioma growth in vivo, 5.0 × 104 K1861
glioblastoma cells were stereotactically injected in the
right striatum of 3-week-old C57Bl/6J mice. Since these
K1861 cells were transduced with a lentiviral vector
expressing green fluorescent protein and firefly luciferase,
tumor growth could be monitored by live bioluminescence
imaging (BLI). We specifically chose to employ the
K1861 glioblastoma for these in vivo experiments, based
on previous studies demonstrating that K1861-engrafted
mice develop large and aggressive intracranial tumors
[19, 23]. Whereas all engrafted mice harbored brain
tumors, there was reduced tumor growth by BLI in the two
K1861 Abcg1 shRNA groups (n = 10 mice/group) relative
to control shRNA K1861-implanted mice (n = 10 mice) at
28 days post-injection (Figure 4A) and the bioluminescent
signal was significantly reduced in both Abcg1 shRNA

Figure 1: Abcg1 expression is associated with poor overall survival in the mesenchymal glioblastoma molecular subtype.

(A) A representative specimen from one adult with a glioblastoma reveals increased ABCG1 expression relative to one representative agematched control brain. Scale bar, 50 μm. (B) Prognostic effect of ABCG1 (high vs. low) in all patients and within each subtype. (C) KaplanMeier analysis demonstrates that increased ABCG1 expression negatively correlated with overall survival in patients with the mesenchymal
glioblastoma subtype (p = 0.004) in GSE16011. (D) In GSE16011, while both age (P = 0.0023) and KPS (P = 0.0037) are associated with
overall survival, multivariate analysis shows that high ABCG1 expression is a strong predictor of poor patient survival, independent of age
and KPS (P = 0.017).
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Figure 2: Abcg1 knockdown reduces NPcis glioma cell growth in vitro. (A) shRNA-mediated Abcg1 knockdown in K1861
NPcis glioma cells. (B) NPcis cells 6 days post-infection with shAbcg1 or control shLacZ virus. Following Abcg1 knockdown, there was
(C) reduced cell growth (% Ki67+ cells) and increased apoptosis (% cleaved caspase 3+ cells). Scale bar, 50 μm. Error bars denote mean ± SD.
(*) p < 0.05.

Figure 3: Abcg1 knockdown increases the ER stress response. shRNA-mediated Abcg1 knockdown in K1861 and K4622
glioblastoma cells increased CHOP and cleaved caspase-3, but not BiP, expression.
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controls (Figure 5). In addition, shAbcg1 K1861 tumors
had increased cell death (TUNEL+ cells). Collectively,
these findings establish Abcg1 as a mediator of ER stressmediated apoptosis and survival in high-grade glioma.

human glioblastoma, where its expression correlates with
overall patient survival. Interestingly, ABCG1 expression
was not associated with survival in patients with all
molecular subtypes of glioblastoma; however, there was
a strong correlation between poor patient survival and
high ABCG1 RNA expression in tumors classified in the
mesenchymal GBM subtype. In this subtype, one of the
signature genetic changes is mutation of the NF1 tumor
suppressor gene [17], which is intriguing, given the
prior identification of ABCG1 as a uniquely upregulated
transcript in GSCs originating from a mouse model of
low-grade glioma harboring biallelic Nf1 gene inactivation
[16, 26]. Importantly, increased Abcg1 expression does not

DISCUSSION
Adaption to ER stress represents one protective
mechanism for sustaining tumor cell growth and
survival in the setting of hypoxia, low glucose levels, or
chemotherapeutic drug exposure [24, 25]. While little is
known about ABCG1 in cancer, we demonstrate for the
first time that ABCG1 is expressed in both murine and

Figure 4: Abcg1 knockdown reduces tumor growth in vivo. (A) Representative bioluminescence images of tumors in engrafted
mice from control shLacZ and shAbcg1 groups (#1, #2) at 28 day post-transplantation were shown. (B) Photon flux of alive mice in all
groups at 4 weeks post-transplantation. Relative to shLacZ-K1861 implanted mice, C57BL/6 mice receiving shAbcg1-K1861 tumors
had reduced bioluminescence signal (#1, p = 0.042; #2, p = 0.0098). Error bars denote mean ± SEM. (C) Kaplan-Meier survival analysis
reveals that mice transplanted with shAbcg1 K1861 NPcis cells exhibit longer survival than those injected with control (shLacZ) NPcis cells
(log-rank test; p < 0.0001).
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focused on additional ER stress pathways in glioblastoma
are currently being explored.
The fact that attenuated ABCG1 expression
significantly prolongs mouse survival following
glioblastoma implantation supports a critical role for
this protein in tumor maintenance. This in vivo effect
was demonstrated both in terms of tumor growth
(bioluminescence imaging and tumor proliferation) and
apoptosis (TUNEL), reminiscent of reported effects of
ABCG2 in high-grade brain tumors. In these studies,
ABCG2 has been implicated in reduced brain penetration
of enhancer of zeste homolog 2 (EZH2) inhibitors [30]
as well as the anti-tumoral responses to PARP inhibitors
(ABT-888) and temozolomide [31]. Moreover, ABCG2
downregulation inhibits glioma stem cell migration and
invasion [32, 33], where its expression partly dictates
the behavior of the side population of high-grade GSCs
[9, 34]. These exciting observations prompted recent
discovery efforts to identify potential modulators of
ABCG2 [35]. As the etiologic mechanisms responsible
for ABCG1-mediated suppression of ER stress and glioma
survival become elucidated [36–41], future therapeutic
strategies designed to blocking these adaptations
may improve treatment efficacy for this deadly brain
malignancy.

result from Nf1 loss directly, but is rather a consequence of
GSC development. In this regard, only optic glioma stem
cells, but not Nf1-deficient NSCs, exhibit increased Abcg1
expression [16]. While it is currently not known how
ABCG1 expression is regulated, a recent study conducted
in CHO cells implicated E3-ubiquitin ligases (HUWE1
and NEDD4-1) in the post-translational regulation of
ABCG1 protein stability and cholesterol export [27].
Formal demonstration of an ubiquitin ligase pathway
that coordinately regulates neurofibromin and ABCG1
expression in glioma warrants further investigation
[28, 29].
Similar to our findings in LG-GSCs, reduced
Abcg1 protein expression using two different shRNA
targeting constructs in two independently-generated
NPcis glioblastoma lines (K1861 and K4622) increased
the expression of CHOP, a final effector of the ER stress
response, and resulted in higher levels of tumor cell death
by apoptosis. However, in contrast to optic glioma stem
cells, some molecular elements of the ER stress pathway
were not conserved in glioblastoma cells. In this regard,
we did not observe any changes in BiP expression, PDI
expression, or PERK phosphorylation (data not shown),
suggesting that other ABCG1-dependent mechanisms
for inducing ER stress may be operative. Further studies

Figure 5: Abcg1 knockdown increases glioblastoma apoptosis in vivo. Glioma sections from control mice (shLacZ) reveal

reduced Abcg1 immunostaining relative to mice harboring tumors with shAbcg1 knockdown. Following Abcg1 knockdown, there was
decreased glioma growth (% Ki67+ cells) and increased apoptosis (% TUNEL+ cells). Error bars denote mean ± SD. (*) p < 0.05.
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MATERIALS AND METHODS

Human specimens and immunostaining
The use of human subject materials was approved by
the institutional review board of the Washington University
School of Medicine. Sixteen intracranial glioblastomas
(WHO grade IV) and seven surgically obtained brain
control cases were identified. Corresponding formalinfixed paraffin-embedded blocks from the pathology
archives were used for immunohistochemistry. Paraffin
sections were processed [44] prior to staining with
appropriate antibodies (Table S2). The TUNEL labeling
was performed using a fluorescence-based in situ cell
death detection kit (Roche Diagnostics). The numbers of
Ki67+ and TUNEL-positive cells were counted within the
tumors per surface area (0.1 mm2).

Cell lines and mice
Mouse malignant glioma NPcis cell lines, K1861
and K4622, were derived from C57BL/6J Trp53+/−/Nf1+/−
mice (Dr. Karlyne Reilly, National Cancer Institute)
[22]. These lines were maintained at 37˚C in 5% CO2 in
Dulbecco’s modified Eagle medium containing 10% fetal
bovine serum. All mouse procedures were performed in
accordance with an approved Animal Studies protocol at
Washington University.

Lentivirus infections
Prior to the lentiviral shAbcg1 infection, NPcis
cells were transduced with lentiviral FUW-GL vector
(Dr. Joshua Rubin) for bioluminescence imaging. Abcg1
shRNA or control shLacZ-containing pLKO.1 plasmid
was co-transfected with pMDLg/pRRE, pRSV-REV and
pCMV-VSV-G into HEK293T cells using the FuGENE
HD transfection reagent (Roche). NPcis cells were
dissociated into single cells by trypsin and transduced with
viral supernatants from HEK293T cells with polybrene
(8 μg/mL) for 48 hours. The knockdown efficiency of
the Abcg1 shRNA constructs was evaluated by Western
blotting. Lentiviral constructs used are listed in Table S1.

Bioluminescence imaging
Animals were given 150 μg/mL D-luciferin
(Gold Biotech) in PBS through intraperitoneal injection
and imaged with a charge-coupled device (CCD) camerabased bioluminescence imaging system (IVIS50; PerkinElmer, Hopkinton, MA) with exposure time 10 secs 1minute, binning 8, field of view 12, f/stop 1, open filter.
Signal was displayed as photons/sec/cm2/sr [45].

Survival outcome analyses
The survival outcome analyses were performed
on the GSE16011 dataset using the R package “RMS”.
Each GBM sample (159 out of 276 total samples) was
assigned to a TCGA subtype (Classical, Mesenchymal,
Neural, or Proneural) based on the 10-nearest neighbors
algorithm as previously described [46]. Kaplan-Meier
survival plots were generated, along with log rank tests,
to compare survival differences between the low/highexpression groups. Multivariate Cox models were fitted
to gene expression (binary format, as dichotomized by the
median) with incorporation of classic clinicopathological
parameters (e.g., TCGA molecular subtype, age and KPS)
to assess the independent prognostic ability of the
candidate gene by the adjusted hazard ratio and associated
95% confidence interval (CI). Age and KPS were
incorporated in the format of restricted cubic spline basis
function with three knots in order to relax the linearity
assumption.

Western blotting
Western blotting was performed as previously
reported [42] using the primary antibodies listed in Table S2.

Intracranial injections
Injections were performed as previously described
[43]. 3 to 5-week-old male wild-type C57BL/6J purchased
from Taconic were used. NPcis cells were prepared in a
2.5 × 104 cell/μL PBS solution and 2 μL (5 × 104) cells
were sterilely implanted intracranially into the right
side striatum using a stereotactic device (coordinates =
posterior 3 mm from the bregma, lateral 1.5 mm (right),
and depth 2.5 from dura mater). Mice were monitored and
euthanized after neurological symptoms developed.

In vitro cell proliferation and death
Statistical analysis

NPcis cells were trypsinized and plated onto 50 μg/
mL poly-D-lysine-coated and 10 μg/mL fibronectin-coated
24-well plates in defined culture medium. After 24 hours,
cells were fixed in 4% paraformaldehyde. Proliferating
and apoptotic cells were detected using antibodies to Ki67
and cleaved caspase-3, respectively. The percent of Ki67+
or cleaved caspase-3+ cells were determined as a percent
of the total cell number (DAPI+ cells).
www.impactjournals.com/oncotarget

Each experiment was performed with samples from
at least three independent groups. All data were processed
and graphed in Prism GraphPad 6.0 with descriptive
statistics calculated. The difference between experimental
groups was assessed by one-way ANOVA. Survival
curves were generated by the Kaplan-Meier method, and
the Log-rank (Mantel-Cox) test was used to compare
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between/among treatments. All tests were two-sided with
a significance level of 5% unless otherwise noted.
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